Follow The Filings

ANIK Anika Therapeutics

Anika Therapeutics earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 6 Nov EPS 0.17 — —
Rev $29.4M — —

Insider trades

Open-market buys and sales by ANIK's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ANIK insider trades
  • $264K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Gary P Fischetti Director
    Buy
    $41K 2,000 shares at $20.53 +3.8% to stake
    Traded Aug 3–4 Filed Aug 5
    ↗
  2. John B Henneman III Director
    Buy
    $73K 5,000 shares at $14.66 +10% to stake
    Traded May 1 Filed May 4
    ↗
  3. Stephen D. Griffin CEO
    Buy
    $150K 12,200 shares at $12.29 +51% to stake
    Traded Apr 30 Filed Apr 30
    ↗

Also filed in the last 12 months, not counted as buying or selling: 11 share withholdings for taxes, 11 option exercises, and 9 stock grants.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
DEFA14A Filing Doc
DEFA14A Filing Doc
10-Q FORM 10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K FORM 10-K Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q FORM 10-Q Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf